APVO earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -0.01. Updated 2026-07-23.
Aptevo Therapeutics (APVO) Research Hub
Aptevo Therapeutics (APVO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.82 USD (-1.62%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.01, market cap 0.01B. This hub links to the full technical, earnings and options research available for APVO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.82 USD (-1.62%) |
| 52-week range | 1.37 USD – 4.91 USD |
| Trend regime | Range |
| 14-day RSI | 6.3 (Oversold) |
| Trailing P/E | -0.01 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for APVO
Covered Call on APVO: how it works, illustrative setup around the real 1.82 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on APVO: how it works, illustrative setup around the real 1.82 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on APVO: how it works, illustrative setup around the real 1.82 USD price, max profit/loss, breakeven and when to use it. Educational.
APVO technical analysis: range, last 1.82 USD, RSI 6.3, 52w range 1.37 USD–4.91 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is APVO in?
Aptevo Therapeutics (APVO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is APVO in an uptrend or downtrend?
As of 2026-09-11, APVO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is APVO's trailing P/E ratio?
APVO's trailing P/E is -0.01, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does APVO next report earnings?
APVO is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -6.02 USD.